Sanofi/Merrimack's anticancer-booster MAb fails to overcome resistant lung cancer
This article was originally published in Scrip
Its MM-121 monoclonal antibody is an important product for Merrimack Pharmaceuticals. The company’s Network Biology platform identified ErbB3, the antibody’s target, as an intervention point in cancers which have become resistant to other treatments. So the failure of the drug in a 50 person Phase II trial in erlotinib-resistance non-small cell lung cancer (NSCLC) could have repercussions beyond this one trial.